Verovaccines

About:

Verovaccines is a biopharmaceutical company.

Website: https://www.verovaccines.org/

Top Investors: HTGF | High-Tech Gruenderfonds, Business Angels Switzerland (BAS), German Federal Ministry of Education and Research

Description:

VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases (proof-of-concept). VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University. VEROVACCiNES GmbH is eligible for follow-up phase 2 funding from the same BMBF GO-Bio program. They cooperate closely with veterinary pharmaceutical companies, universities and research institutes, and they are eager to initiate new collaborations.

Total Funding Amount:

3.1M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Halle, Niedersachsen, Germany

Founded Date:

2017-01-01

Founders:

Hanjo Hennemann, Sven-erik behrens

Number of Employees:

11-50

Last Funding Date:

2021-10-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai